ROIV insider ownership: who sold, why, and what they still hold

What stands out

Eight insiders sold $575M with no disclosed plan: Keith Manchester ($154M), Daniel Gold ($147M) and Mayukh Sukhatme ($109M), plus 5 more. The filings don't state a reason.Keith Manchester: largest such sale, Jun 29, 2026 · Daniel Gold: largest such sale, Jun 29, 2026 · Mayukh Sukhatme: largest such sale, Dec 31, 2025

Outside holder QVT Financial LP, a 10% owner and not part of management, sold $147M of stock.Largest sale, Jun 29, 2026

A share of stake is shown for 0 of the 11 officers and directors who sold. 13 are left out

Left out: Vivek Ramaswamy, Daniel Gold, Keith Manchester, Mayukh Sukhatme, Matthew Gline, Frank Torti, Eric Venker, Richard Pulik, Ilan Oren, Jennifer Humes, James Momtazee, Melissa Epperly and Meghan Fitzgerald (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

Keith Manchester

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$154MNo plan disclosed

Daniel Gold

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$147MNo plan disclosed

Mayukh Sukhatme

President & CIO, Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$109MNo plan disclosed

Vivek Ramaswamy

10% owner

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$106MNo plan disclosed

Eric Venker

President & Immunovant CEO

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$84.3M93% planned, 7% to cover taxes

All 11 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planTo cover taxesNo plan disclosedOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 14, 2026 to Oct 13, 2026

Oct 1, 2026Melissa Epperly sold 18K shares ($641K) under a disclosed trading plan. 18K shares came in from vesting or option exercises the same day, so the holding rose by 0 net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Melissa Epperly Director	17,750	$36.10	n/a	n/a	Oct 1, 2026	Oct 5, 2026

Sep 30, 2026Eric Venker sold 200K shares ($7.3M) under a disclosed trading plan. 200K shares came in from vesting or option exercises the same day, so the holding rose by 0 net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Eric Venker President & Immunovant CEO	200,000	$36.62	n/a	n/a	Sep 30, 2026	Oct 2, 2026

Sep 30, 20262 executives had 123K shares ($4.5M) withheld by the company for taxes (not a market sale).

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Matthew Gline CEO, Director	76,171	$36.57	n/a	n/a	Sep 30, 2026	Oct 2, 2026
Mayukh Sukhatme President & CIO, Director	46,879	$36.57	n/a	n/a	Sep 30, 2026	Oct 2, 2026

Sep 20, 20262 executives had 6K shares ($239K) withheld by the company for taxes (not a market sale).

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Jennifer Humes Chief Accounting Officer	3,880	$39.77	n/a	n/a	Sep 20, 2026	Sep 22, 2026
Richard Pulik CFO	2,129	$39.77	n/a	n/a	Sep 20, 2026	Sep 22, 2026

Sep 15, 20262 directors sold 10K shares ($399K) under a disclosed trading plan.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Meghan Fitzgerald Director	5,112	$39.74	n/a	n/a	Sep 15, 2026	Sep 17, 2026
Melissa Epperly Director	4,938	$39.74	n/a	n/a	Sep 15, 2026	Sep 17, 2026

"% of total stake" is the shares in an event against all the vested shares the person held that day, across every share class and holding entity, after that day's vesting. "n/a" means the person's holdings are not confirmed, or the row is a purchase. "Holdings record incomplete" means more shares were sold than the filings show the person held that day, so a percentage would be wrong.

Outside holders, reported separately

QVT Financial LP sold $147M in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.

Details

Common questions

Is the Roivant Sciences Ltd. CEO selling stock?

Yes. Matthew Gline sold 2.03M shares ($46.2M) in the past 12 months, none of it under a trading plan disclosed in the filings.

Why are Roivant Sciences Ltd. insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 22% of sales by value ran under 10b5-1 trading plans disclosed in the filings, 0.8% were to cover taxes and 77% had no disclosed plan. A trading plan schedules sales in advance.

Are any Roivant Sciences Ltd. insiders buying?

No. Officers and directors reported no purchases in the past 12 months.

The evidence

Who sold11 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Keith Manchester Director	$154M 5.86M shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Daniel Gold Director	$147M 5.66M shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Mayukh Sukhatme President & CIO, Director	$109M 3.70M shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Vivek Ramaswamy 10% owner	$106M 4.96M shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Eric Venker President & Immunovant CEO	$84.3M 3.33M shares	Not confirmed share of stake is being verified. Why	93% under a disclosed plan, 7% to cover taxes
Frank Torti President and Vant Chair	$82.0M 3.00M shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Matthew Gline CEO, Director	$46.2M 2.03M shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Richard Pulik CFO	$9.1M 407K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Meghan Fitzgerald Director	$3.3M 105K shares	Not confirmed share of stake is being verified. Why	41% under a disclosed plan 59% no plan disclosed
Melissa Epperly Director	$2.6M 82K shares	Not confirmed share of stake is being verified. Why	55% under a disclosed plan 45% no plan disclosed
Jennifer Humes Chief Accounting Officer	$384K 14K shares	Not confirmed share of stake is being verified. Why	No plan disclosed

Outside holder, reported separately: QVT Financial LP (a 10% owner, not part of management). Sold $147M (5.66M shares) from Nov 19, 2025 to Jun 30, 2026. Latest filing

The full ownership picture0 of 13 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 13, 2025

Sold

Held Oct 13, 2026

Still held

Vivek Ramaswamy

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Vivek Ramaswamy are complete.

10% owner

n/a

−4.96M

n/a

Vesting, gifts, unvested awards and holding lines for Vivek Ramaswamy

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Vivek Ramaswamy are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
21,856,138	$12.68	Mar 31, 2026	$522M
1,753,905	$13.78	Mar 31, 2026	$40.0M
5,915,052	$15.85	Mar 31, 2026	$123M
22,150,227	$12.68	Mar 31, 2026	$529M

Estimate: options held × ($36.57 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Daniel Gold

Director

n/a

−5.66M

n/a

Vesting, gifts, unvested awards and holding lines for Daniel Gold

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Daniel Gold are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−5.1Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
27,894	$12.19	Sep 9, 2034	$680K
33,726	$13.77	Sep 9, 2035	$769K
10,531	$39.57	Sep 15, 2036	$0

Estimate: options held × ($36.57 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Keith Manchester

Director

n/a

−5.86M

n/a

Vesting, gifts, unvested awards and holding lines for Keith Manchester

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Keith Manchester are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
27,894	$12.19	Sep 9, 2034	$680K
33,726	$13.77	Sep 9, 2035	$769K
10,531	$39.57	Sep 15, 2036	$0

Estimate: options held × ($36.57 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Mayukh Sukhatme

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. See the filing Sales and other transactions for Mayukh Sukhatme are complete.

President & CIO, Director

n/a

−3.70M

n/a

Vesting, gifts, unvested awards and holding lines for Mayukh Sukhatme

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Mayukh Sukhatme are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−311Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
14,224,363	$3.85	Apr 19, 2032	$465M
555,840	$12.68	Mar 31, 2026	$13.3M
95,718	$12.68	Mar 31, 2026	$2.3M
13,224,363	$3.85	Apr 19, 2032	$433M

Estimate: options held × ($36.57 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Matthew Gline

CEO, Director

n/a

−2.03M

n/a

Vesting, gifts, unvested awards and holding lines for Matthew Gline

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Matthew Gline are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−511Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
14,973,184	$3.85	Apr 19, 2032	$490M

Estimate: options held × ($36.57 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Frank Torti

President and Vant Chair

n/a

−3.00M

n/a

Vesting, gifts, unvested awards and holding lines for Frank Torti

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Frank Torti are complete; balances and unit counts will be added when the check is finished.

−110Kgifted (net of own trusts)

−200Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
1,606,249	$11.03	Sep 19, 2028	$41.0M
585,240	$11.50	Apr 21, 2029	$14.7M
146,310	$10.08	Aug 19, 2029	$3.9M
219,465	$13.07	May 19, 2030	$5.2M
562,731	$10.00	May 1, 2031	$15.0M
1,125,460	$10.00	May 1, 2031	$29.9M
3,026,184	$3.85	Apr 19, 2032	$99.0M

Estimate: options held × ($36.57 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Eric Venker

President & Immunovant CEO

n/a

−3.33M

n/a

Vesting, gifts, unvested awards and holding lines for Eric Venker

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Eric Venker are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−62Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
3,644,834	$3.85	Apr 19, 2032	$119M
409,000	$10.80	Jul 25, 2034	$10.5M

Estimate: options held × ($36.57 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Richard Pulik

CFO

n/a

−407K

n/a

Vesting, gifts, unvested awards and holding lines for Richard Pulik

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Richard Pulik are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−35Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
740,000	$3.85	Apr 19, 2032	$24.2M
302,594	$10.60	Apr 21, 2034	$7.9M
180,413	$10.04	Apr 20, 2035	$4.8M
84,026	$29.08	Apr 19, 2036	$629K

Estimate: options held × ($36.57 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Ilan Oren

Director

n/a

Vesting, gifts, unvested awards and holding lines for Ilan Oren

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Ilan Oren are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−2.9Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
27,894	$12.19	Sep 9, 2034	$680K
33,726	$13.77	Sep 9, 2035	$769K
10,531	$39.57	Sep 15, 2036	$0

Estimate: options held × ($36.57 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Jennifer Humes

Chief Accounting Officer

n/a

−14K

n/a

Vesting, gifts, unvested awards and holding lines for Jennifer Humes

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jennifer Humes are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−22Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
115,108	$10.97	Mar 19, 2035	$2.9M
27,157	$29.08	Apr 19, 2036	$203K

Estimate: options held × ($36.57 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

James Momtazee

Director

n/a

Vesting, gifts, unvested awards and holding lines for James Momtazee

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for James Momtazee are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−3.3Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
27,894	$12.19	Sep 9, 2034	$680K
33,726	$13.77	Sep 9, 2035	$769K
10,531	$39.57	Sep 15, 2036	$0

Estimate: options held × ($36.57 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Melissa Epperly

Director

n/a

−82K

n/a

Vesting, gifts, unvested awards and holding lines for Melissa Epperly

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Melissa Epperly are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−2.2Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
151,416	$4.46	Jul 19, 2032	$4.9M
27,894	$12.19	Sep 9, 2034	$680K
33,726	$13.77	Sep 9, 2035	$769K
10,531	$39.57	Sep 15, 2036	$0

Estimate: options held × ($36.57 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Meghan Fitzgerald

Director

n/a

−105K

n/a

Vesting, gifts, unvested awards and holding lines for Meghan Fitzgerald

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Meghan Fitzgerald are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−1.7Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
18,578	$8.80	Apr 19, 2033	$516K
27,894	$12.19	Sep 9, 2034	$680K
33,726	$13.77	Sep 9, 2035	$769K
10,531	$39.57	Sep 15, 2036	$0

Estimate: options held × ($36.57 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Holdings and share of stake for Roivant Sciences Ltd. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$745M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $745M across 29,136,447 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $163M · 22%

78%

The lighter segment is sales with no plan disclosed in the filing ($582M), including tax-related sales outside a plan.

No plan disclosed · $576M

Sales with no 10b5-1 plan and no tax reference in the filing. $154M of it is Keith Manchester. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Vivek Ramaswamy, Dec 12, 2025

Taxes

$6.2M of sales (0.8%) cite tax obligations in their footnotes. Separately, 1,156,902 shares ($34.9M) were withheld by the company for taxes, which isn't a market sale. Example: Eric Venker, Dec 24, 2025

Charitable gifts · 110K shares

Gifts the filings describe as charitable. Gifts are not sales and are not included in the sale totals.

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Keith Manchester Director	5.86M	$154M	0%	21%	Nov 19, 2025 to Jun 30, 2026
Daniel Gold Director	5.66M	$147M	0%	20%	Nov 19, 2025 to Jun 30, 2026
Mayukh Sukhatme President & CIO, Director	3.70M	$109M	0%	15%	Dec 17, 2025 to Aug 21, 2026
Vivek Ramaswamy 10% owner	4.96M	$106M	0%	14%	Nov 13, 2025 to Dec 15, 2025
Eric Venker President & Immunovant CEO	3.33M	$84.3M	93%	11%	Oct 15, 2025 to Sep 30, 2026
Frank Torti President and Vant Chair	3.00M	$82.0M	100%	11%	Feb 19, 2026 to Feb 23, 2026
Matthew Gline CEO, Director	2.03M	$46.2M	0%	6%	Dec 15, 2025 to Apr 16, 2026
Richard Pulik CFO	407K	$9.1M	0%	1%	Dec 23, 2025 to Dec 23, 2025
Meghan Fitzgerald Director	105K	$3.3M	41%	0.4%	Mar 26, 2026 to Sep 15, 2026
Melissa Epperly Director	82K	$2.6M	55%	0.4%	Mar 16, 2026 to Oct 1, 2026
Jennifer Humes Chief Accounting Officer	14K	$384K	0%	0.1%	Apr 8, 2026 to Apr 8, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$14.5M	$14.5M	$0	$0
Nov 2025	$94.6M	$4.0M	$0	$90.5M
Dec 2025	$233M	$4.2M	$6.2M	$222M
Jan 2026	$4.4M	$4.4M	$0	$0
Feb 2026	$162M	$87.3M	$0	$74.3M
Mar 2026	$8.8M	$5.6M	$0	$3.1M
Apr 2026	$14.8M	$5.9M	$0	$8.8M
May 2026	$6.1M	$6.1M	$0	$0
Jun 2026	$147M	$7.6M	$0	$140M
Jul 2026	$7.0M	$7.0M	$0	$0
Aug 2026	$43.7M	$7.2M	$0	$36.5M
Sep 2026	$8.5M	$8.5M	$0	$0
Oct 2026	$641K	$641K	$0	$0

Is this normal? Selling year by year4 earlier years to compare with

More than usual: about 2.3x the 4-year average. 10 insiders sold; the average is 4 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 13, 2026 Latest 12 months	17.82M	10	$450M
Oct 13, 2025 1 year earlier	12.13M	4	$150M
Oct 13, 2024 2 years earlier	9.33M	6	$107M
Oct 14, 2023 3 years earlier	8.69M	5	$79.8M
Oct 14, 2022 4 years earlier	816K	3	$3.6M
Oct 14, 2021 5 years earlier · filings don't cover the whole year	n/a	n/a	n/a

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty13 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Roivant Sciences Ltd. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology458 filings on record, 96 filed in the 12-month period, and how we read them

All 458 Forms 3, 4 and 5 on record for Roivant Sciences Ltd. (SEC CIK 1635088), filed from Oct 1, 2021 to Oct 5, 2026; 96 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 13, 2026. Prices are the ones reported in each filing, often weighted averages. 40 filings were left out because Roivant Sciences Ltd. filed them as an owner of another company's stock.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (10)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
Rakhi Kumar	Feb 24, 2025	162,306 shares, last reported balance as of Feb 20, 2025
SVF Investments (UK) Ltd	Oct 2, 2023	73,031,667 shares, last reported balance as of Sep 28, 2023
Sumitomo Chemical Co., Ltd.	Jun 26, 2023	157,618,443 shares, last reported balance as of Jun 22, 2023
VIKING GLOBAL INVESTORS LP	Jun 26, 2023	12,884,307 shares, last reported balance as of Jun 22, 2023
Dexcel Pharma Technologies Ltd.	Nov 14, 2022	102,849,443 shares, last reported balance as of Nov 10, 2022
Andrew Lo	Sep 19, 2022	52,142 shares, last reported balance as of Sep 15, 2022
Benjamin Zimmer	Oct 1, 2021	169,924 shares, last reported balance as of Oct 1, 2021
Patrick Machado	Oct 1, 2021	No balance on record
Masayo Tada		No balance on record
Hiroshi Nomura		No balance on record

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Roivant Sciences Ltd. insiders sold $745M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Outside holders, reported separately

Common questions

Is the Roivant Sciences Ltd. CEO selling stock?

Why are Roivant Sciences Ltd. insiders selling?

Are any Roivant Sciences Ltd. insiders buying?

The evidence

No plan disclosed · $576M

Taxes

Charitable gifts · 110K shares

Sales by month